Drug Profile

Research programme: anticancer splice-switching oligonucleotides - Envisagenics

Latest Information Update: 13 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Preclinical Breast cancer
Research Acute myeloid leukaemia; Colorectal cancer; Lung cancer; Multiple myeloma

12 Feb 2026 Envisagenics has patent protection for systems and methods for analysis of alternative splicing in Australia
12 Feb 2026 Envisagenics has patents pending for systems and methods for analysis of alternative splicing in Japan, China, Europe, Canada and USA
12 Feb 2026 Envisagenics has patents pending for systems and methods for identifying and using alternative splicing derived cell surface antigens in USA and Europe

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com